Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of Cancer and Leukemia Group B 9013 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Interferon-alpha
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Mental Disorders
  • Neurotoxicity Syndromes

abstract

  • CML patients with a pretreatment history of a neurologic or psychiatric diagnosis are at significantly increased risk of developing severe neuropsychiatric toxicity during therapy with rIFNalpha2b plus cytarabine. Monitoring for neuropsychiatric symptoms and avoiding rechallenge are recommended measures for such patients receiving rIFNalpha2b-based therapy.

publication date

  • March 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10715301

Additional Document Info

start page

  • 1301

end page

  • 8

volume

  • 18

number

  • 6